Navigation Links
New York's Medical Schools urge Congress to preserve NIH funding for scientific research
Date:12/4/2012

The Associated Medical Schools of New York (AMSNY) today directed a letter to the New York State Congressional Delegation calling on them to reject a nearly 10-percent cut to the National Institutes of Health (NIH), Medicare and Title VII health professions programs, that will take effect January 2, 2013.

"In order to meet the health challenges of an aging and increasingly diverse population, continue to foster the types of innovation that will drive our regional economy, and remain a vibrant force in the global economy, we need to invest more in medical research and the health care workforce, not less," said Dr. Lee Goldman, AMSNY's chair, and executive vice president and dean of the Columbia University College of Physicians & Surgeons. "Cuts to vital research and educational programs will delay medical progress and deny hope to millions of Americans."

The AMSNY letter states that "the Office of Management and Budget (OMB) estimates the pending sequestration action will reduce NIH funding in FY 2013 by $2.5 billion. Medical schools and teaching hospitals would lose more than $1 billion nationally. Approximately $167 million in funding would be lost in New York State alone. According to a 2010 Tripp Umbach report commissioned by AMSNY, the state receives an economic return of $7.50 for each research dollar invested in New York's medical schools. Therefore, a $167 million loss in NIH funding would equate to an overall loss of approximately $1.25 billion to New York's economy and result in lost jobs."

"The high quality of medical care we enjoy today is built upon years of effort by physicians, scientists and other medical professionals investigating the causes of, and potential treatments for, disease," said Dr. Goldman. "For millions of patients and their families, medical research means hope. It is the promise for a future that will alleviate pain and illness for those suffering from diseases such as cancer, diabetes, Alzhe
'/>"/>

Contact: Crystal Mainiero
crystalmainiero@amsny.org
212-218-4610
Columbia University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Sharp spike in computer-related injuries predicted for medical workers, find studies
2. FDA to Collaborate on Development of Medical Devices
3. DFG funds new Collaborative Research Center at the Mainz University Medical Center
4. Dr. Deluca of Kessler Foundation receives medical excellence award for MS research
5. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
6. Society of Diagnostic Medical Sonography Foundation introduces Sonography Research Institute
7. Costly, Repeat Medical Testing Common for Medicare Patients: Study
8. Authors of landmark study on infant mortality and electronic medical records receive Garfield Award
9. International survey: 69 percent of US primary care doctors now have electronic medical records
10. UTSW 1 of 2 academic medical centers to win 2 major patient satisfaction awards
11. LA BioMed celebrates 60 years of medical achievements at the Gift of Tomorrow Gala
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where different ... signatures within the same cancer. Such differences could ... strategies. , Firstly they confirmed the mutual exclusivity ... or BRAF mutation. Secondly, they found that lung ... that specific mutation present uniformly throughout the tumour, ...
(Date:4/23/2014)... to the bottom of Alzheimer,s disease has been ... and controversies. In the latest crook in the ... into the interaction between proteins associated with the ... ACS Chemical Neuroscience , could have important ... Surewicz, Krzysztof Nieznanski and colleagues explain that for ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... UT Southwestern Medical Center are making breakthroughs that could ... A team of physician-scientists at UT Southwestern has identified ... natural anti-depressant properties) works inside the brain. Simultaneously, the ... in the form of a neuroprotective drug known as ... April,s issue of Molecular Psychiatry, is notable ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3
... in no real danger, survey finds , MONDAY, Aug. 20 ... white peers to take risks that boost their odds for ... August issue of the journal Archives of Dermatology , ... Medicine surveyed 369 high school students (221 white Hispanics and ...
... are exposed to more pro-tobacco advertising, according to a ... this months Public Health Reports. , Smoking remains ... the United States, causing more than 440,000 deaths annually ... indirect costs each year; African-Americans currently bear the greatest ...
... In a study likely applicable to men of other ... than 21 drinks per week) may increase the risk ... study are published in the latest issue of Annals ... Lydia Bazzano of Tulane University School of Public Health ...
... sounds like the latest cleaning sensation being hawked on ... get in your eyes. , But a few properly ... to diagnosing dry eye syndrome earlier than other methods, ... disease, new research at UT Southwestern Medical Center confirms. ...
... to new treatments, study says , SUNDAY, Aug. 19 ... most red, purple and blue fruits and vegetables, may help ... , In laboratory tests on rats and on human colon ... the growth of colon cancer cells. The team also found ...
... It affected 4 indicators of cardiovascular trouble, study found ... air drags down a number of "biological indicators" pointing ... shows. , The indicators include autonomic dysfunction, inflammation, oxidative ... was published Aug. 15 in the American Journal ...
Cached Medicine News:Health News:Hispanic Teens Take More Skin Cancer Risks 2Health News:Pitt study finds inequality in tobacco advertising 2Health News:Eye-staining technique offers early detection for dry eye syndrome 2Health News:Eye-staining technique offers early detection for dry eye syndrome 3Health News:Urban Smog Tough on Young Adults' Hearts 2
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, today ... of VELCADE based therapies that showed consistently high,complete ... multiple,myeloma (MM). CR is one of the best ... for oral presentation at the American Society,of Clinical ...
... reduced the risk of cancer returning or death by 36% beyond clinical ... alone(1) - Findings may allow clinicians to improve standard of care ... ... - These are the first data from a large clinical program exploring ...
Cached Medicine Technology:Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 2Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 3Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 4Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 5Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 6Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 7Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 8Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer 9
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: